EMA to review Marketing Authorisation of GW Pharma’s cannibidiol

EMA has accepted GW Pharmaceuticals’ request to review the MMA (Marketing Authorisation Application) of Epidiolex, or cannibidiol. The treatment is currently used on patients who suffer from seizures linked to Lennox-Gastaut syndrome and Dravet syndrome. GW Pharmaceuticals first submitted Epidiolex for review in December 2017. The successful filing of the MAA of the drug follows

Continue Reading

MHRA accept Roche’s bladder cancer immunotherapy drug for Early Access to Medicines Scheme

Roche’s Tecentriq has scored another positive opinion. The Medicines and Healthcare products Regulatory Agency (MHRA) has recently accepted the immunotherapy drug into the Early Access to Medicines Scheme (EAMS) for the treatment advanced bladder cancer. The decision means that patients suffering from bladder cancer could have access to the drug while it awaits decision from

Continue Reading